Cytokinetics

Cardiovascular system
#Cardiovascular disease #Cytokinetics #MHRA #National Institute for Health and Care Excellence (NICE)

Myqorzo gets concurrent approvals from UK’s MHRA and NICE

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Myqorzo (aficamten) a marketing authorisation across the UK for the treatment of symptomatic (New York Heart Association, NYHA class II-III) obstructive hypertrophic cardiomyopathy (oHCM).   At the same time, the National Institute for Health and Care Excellence (NICE) has issued guidance… Read More

#News #Regulatory